雜志介紹

Journal Of Biopharmaceutical Statistics雜志介紹

《Journal Of Biopharmaceutical Statistics》是一本以English為主的未開(kāi)放獲取國(guó)際優(yōu)秀期刊，中文名稱生物制藥統(tǒng)計(jì)雜志，本刊主要出版、報(bào)道醫(yī)學(xué)-PHARMACOLOGY & PHARMACY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為1.2，最新CiteScore 指數(shù)為2.5。

本刊近期中國(guó)學(xué)者發(fā)表的論文主要有：

• Confidence intervals of mean residual life function in length-biased sampling based on modified empirical likelihood

  Author: Ratnasingam, Suthakaran; Ning, Wei

• Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpoint

  Author: Ni, Senmiao; Yu, Quanji; Zhong, Zihang; Yang, Min; Zhao, Yang; Wu, Jingwei; Bai, Jianling; Yu, Hao

• A randomized Bayesian optimal phase II design with binary endpoint

  Author: Ding, Yang

• Modelling non-linear patterns of time-varying intervention effects on recurrent events in infectious disease prevention studies

  Author: Cheung, Yin Bun; Ma, Xiangmei; Lam, K. F.; Yung, Chee Fu; Milligan, Paul

英文介紹

Journal Of Biopharmaceutical Statistics雜志英文介紹

The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:

Drug, device, and biological research and development;

Drug screening and drug design;

Assessment of pharmacological activity;

Pharmaceutical formulation and scale-up;

Preclinical safety assessment;

Bioavailability, bioequivalence, and pharmacokinetics;

Phase, I, II, and III clinical development including complex innovative designs;

Premarket approval assessment of clinical safety;

Postmarketing surveillance;

Big data and artificial intelligence and applications.